IsoRay, Inc. Announces Launch of Newly Redesigned Patient and Clinician Focused Corporate Website

Sep 28, 2016

Expanded Information and Resources for Brachytherapy and its Efficacy with Multiple Cancers

RICHLAND, Wash.Sept. 28, 2016 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the launch of its newly redesigned corporate website at

The redesigned website introduces IsoRay’s new branding and logo and offers quick and easy access to essential information that provides a comprehensive understanding of the Company’s innovative Cesium-131 products. It is both patient and clinician focused and has an updated visual design and content structure which will make it easier for patients and medical teams to find what they’re looking for. FAQ’s are front and center for quick access to popular questions. The website also has a comprehensive investor section with updated company news and events, financial and stock information, SEC filings and corporate governance information.  The Company’s new branding was also incorporated in physician materials at this week’s American Society for Radiation Oncology (Astro) Annual Meeting in Boston.

The site was built with a flexible content management system to facilitate ongoing updates. Over time, more and more content will be added including patient stories, clinician experiences and peer-reviewed publications.

“The launch of IsoRay’s new website, with our new branding and logo, represents the patient and clinician focus of the Company under the new management team,” said Thomas LaVoy, Chairman and CEO of IsoRay.  “The robust information it delivers for all of our constituencies is intended to increase awareness of brachytherapy and its efficacy with multiple cancers as well as provide a better understanding of the benefits of IsoRay’s innovative Cesium-131 patient solutions and offer important resources to enable expanded use of our product applications.”

About IsoRay, Inc.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting Join us on Facebook/IsoRay. Follow us on Twitter @IsoRay.

Safe Harbor Statement

Statements in this news release about IsoRay’s future expectations, including: the advantages of our products and their delivery systems, whether interest in and use of our products will increase or continue, whether the newly redesigned website will increase patient or clinician engagement and interest, what content will be included in future updates of the website, whether the FAQs or other information provided address the concerns of the patient or clinician, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay’s reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Logo –

Investor Relations:

Mark Levin

Global IR Group
(501) 255-1910

Media and Public Relations:

Sharon Schultz
Schultz Public Relations
(302) 539-3747